AceLink Therapeutics, Inc
AceLink Therapeutics, Inc. is a clinical-stage drug development company based in Newark, CA, specializing in groundbreaking therapies for diseases related to glycolipid metabolism. The company boasts a seasoned team of professionals with extensive knowledge in glycolipid biology, rare genetic diseases, and drug development, collaborating with a broad network of research organizations and academic leaders.
Among its lead programs, AL1211 is a non-brain penetrant glucosylceramide synthase (GCS) inhibitor currently undergoing Phase 2 trials for Fabry disease and type I Gaucher disease. Additionally, AL0804, a highly brain-penetrant GCS inhibitor, targets neuronopathic glycolipid storage diseases, while AL1311 is a potent NRF2 activator being developed for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.

